Company Introduction
NE Engineering, entered the China market in 1995 and has continuously serviced this market for over two decades. Over 2000 consultant projects and more than 50 EPCMV were successfully completed during this period of time.
NE Engineering is capable of providing full and sustainable services including consulting, design and engineering, project management, procurement, and GMP validation to customers in the Pharmaceutical and Life Sciences industries.
NE's services are tailored to the highly GMP-regulated pharmaceutical industry. We call this focused pharma engineering. We support the entire pharma manufacturing lifecycle from setting direction, realising benefits of strategic investments and optimising manufacturing and business processes. We help customers from manufacturing development to manufacturing transformation, implementation of pharma organisational change management and optimisation. Our goal is to help customers achieve and maintain optimal GMP manufacturing and bring products to market.
Since Dec. 2018, NE operates as an independent entity, that has the flexibility to operate on market conditions in China. NE inherited all NNE's personnel talents, technical competence and industry reputation developed in China and NE is the sole designated partner for NNE in all business in China. NE operate in a close cooperation with NNE as needed on a project by project basis - regulated by a teaming agreement. In particularly, we draw on expertise where needed from our sister companies.
Culture
Honesty Responsibility Teamplay Agility Customer centricity Solution orientation
Vision
We want to be a brick in the wall of human health, and we will continue to make our mark in pharma engineering.
Mission
Engineering for a healthier world.
Company History
First mover
In 1995 NNE moves into China as one of the first advisors to pharmaceutical and biotech companies.Today,we have 100 employees in our offices in Tianjin and Shanghai. This timeline shows highlights from our journey in China.
1995
First mover
In 1995 NNE moves into China as one of the first advisors to pharmaceutical and biotech companies.Today,we have 100 employees in our offices in Tianjin and Shanghai.
This timeline shows highlights from our journey in China.
NNE opensa project office in Tianjin, outside of Beijing, to help Novozymes estalish their first enzyme production facility in the country.
1998
With the help of NNE, Novozymes opens a plant with advanced technology within fermentation, recovery and granulation in Tianjin TEDA. In the following years, NNE continues the design, procurement, construction and commissioning service for the facility.
2004
NNE establishes an office in Tianjin to cover all customer projects in China. Kristian Pedersen takes up the position of General Manager of China.
2005
NNE starts the design for Novozymes Suzhou Hongda enzyme production plant in Taicang Jiangsu.
2006
NNE starts the design for Novozymes Suzhou Hongda enzyme production plant in Taicang Jiangsu.
2007
NNE establishes an office in Shanghai in order to stay close to its pharma customers, as they increasingly pursue production opportunities around the location.
As part of a Global Strategy, NNE acquired Pharmaplan and become NNE Pharmaplan.
2008
NNE Pharmaplan provides a team of 75 employees accross all engineering disciplines for the design and construction for a new 88000㎡ facility for Novo Nordisk in Tianjin.
2009
NNE Pharmaplan starts the design for Novozymes bHA EPCMV project in TEDA which is the first biopharm facility for Novozymes in China.
2010
PCMV services. This is a big breakthrough and an important milestone for our cooperation with AstraZeneca in China.
NNE Pharmaplan builds the first FDA-approved biotech facility for Novozymes in Tianjin.
NNE Pharmaplan obtains a design license class B on Chemical, Petrochemical and Pharmaceutical Engineering, which grants the right to issue drawings for construction and act as general contractor. NNE Pharmaplan is one of the first international companies to obtain this in its own name.
2011
NNE Pharmaplan completes the whole engineering package（EPCMV）for GSK Biologicals for the revamp of an influenza vaccine facility in Shenzhen-a project which strengthened our leading position in the vaccine industry in China.
2012
NNE Pharmaplan provides engineering, procurement, construction, management and qualification for the Roche plant in Shanghai.
NNE Pharmaplan completes 'Blair' project, the world’s most advanced enzyme plant for biofuel for Novozymes. In one of the largest cross-regional collaborations in NNE Pharmaplan’s history, prefab plant modules are transferred from China to the US. NNE Pharmaplan establishes a 9,000m2 assembly yard in Ning Bo, south of Shanghai, where complete module frames are erected, tank equipment is welded and extensive piping is mounted for each module.
2013
NNE Pharmaplan designs Boehringer Ingelheim’s first greenfield biotech facility in Asia based on NNE Pharmaplan’s standard biotech facility concept known as ‘Bio on demand™’.
2014
NNE Pharmaplan hands over a new manufacturing facility for OSD products for AstraZeneca to meet the high demand for blood pressure medication in China. NNE is involved in all phases of the project from the concept to the production validation.
NNE Pharmaplan starts the basic design service for Wuxi Apptec manufacturing facility.
2015
AstraZeneca is awarded the 2015 Facility of the Year Award by ISPE in the Project Execution Category – a project NNE Pharmaplan designs and manages.
NNE Pharmaplan helps Roche expand their Oral Solid Dosage production in Shanghai – their third most important site globally.
2017
NNE Pharmaplan changed its company name to NNE .
QIAGEN is planning to relocate their existing production facility to Pingshan, Shenzhen. NNE provided EPCMV service for this project, starts from site selection till I/OQ finish.
2018
Henlius was a pioneer in introducing single use biotechnology in China. Bio-Pharm manufacturing plant project is a milestone in the development of Henlius, and of Chinese biotechnology. And we were fortunate enough to be part of this development.
Since Dec. 2018, NE operates as an independent entity, that has the flexibility to operate on market conditions in China. NE Engineering inherited all NNE's personnel talents, technical competence and industry reputation developed in China and NE Engineering is the sole designated partner for NNE in all business in China. NE Engineering operate in a close cooperation with NNE as needed on a project by project basis - regulated by a teaming agreement. In particularly,we draw on expertise where needed from our sister companies.
2018
Phase 2 expansion is for the upstream production line capacity increasing and all related supporting functions, including production, warehouse, QC labs, CUB, and WWTP. NE Engineering provides the feasibility study, engineering, and validation service.
2018
Gracell is planning to establish a new chimeric antigen receptor T cell (CAR-T) manufacturing facilities in an existing building in Suzhou. NE Engineering provide the Conceptual Design and Basic Design service within 19 weeks to fulfil Gracell’s schedule for this project.
2019
Porton intends to establish a GMP development facility for monoclonal antibodies in an existing 5 storey building in Suzhou, the total area is 3505sqm. NE performed the whole Feasibility Study, Conceptual Design and Basic Design packages for this project. The 3D modelling and VR providing its customers a virtual real fairly intuitive accessibility.
2019
Novo Nordisk wants to have a GSP license within Tianjin. B800 small ambient warehouse is to be modified for future GSP ambient warehouse, meanwhile B800 big ambient warehouse is upgraded to increase storage capacity. NE is responsible for EPCMV package.
2019
To increase the manufacturing capacity, Siemens Healthcare Diagnostics launched the Draco project to fit-out the level 3 of building D to establish the Pre-Production Area (PPA) pilot plant in the existing Pudong site. NE is providing the commissioning, qualification and validation service, as well as HVAC and electrical support form October 2018 to March 2020.